Filter results
21/03/2023
ROVI joins BioSim to strengthen initiatives that promote greater access to and knowledge about biosimilar medicines.
21/02/2023
ROVI reports operating revenue growth of 26% and EBITDA growth of 37%
16/02/2023
ROVI has now filed the final responses to the Complete Response Letter received from the United States Food and Drug Administration (FDA) in the third quarter of 2022
06/02/2023
The Minister, Alexandru Rafila, was accompanied by the Director of Cabinet of the Romanian Ministry of Health and the Romanian Ambassador to Spain.